Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$2.92 -2.0%	$3.93	$2.76 ▼ $6.98	$144.36M	1.21	180,173 shs	391,898 shs
INMB INmune Bio	$2.53 +3.3%	$3.89	$1.89 ▼ $11.64	$67.26M	0.97	2.97 million shs	527,682 shs
KRON Kronos Bio	$0.88 +1.5%	$0.81	$0.65 ▼ $1.46	$53.72M	1.64	370,931 shs	54,089 shs
LRMR Larimar Therapeutics	$4.01 -5.9%	$3.29	$1.61 ▼ $9.50	$331.94M	0.93	1.73 million shs	1.88 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	0.00%	+1.39%	-29.98%	-28.78%	-50.42%
INMB INmune Bio	0.00%	-1.17%	+12.95%	-67.81%	-62.41%
KRON Kronos Bio	0.00%	0.00%	0.00%	+29.18%	-10.80%
LRMR Larimar Therapeutics	0.00%	+12.01%	+20.78%	+102.53%	-47.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	2.5236 of 5 stars	3.3	2.0	0.0	0.0	2.1	1.7	1.3
INMB INmune Bio	2.0087 of 5 stars	3.3	2.0	0.0	0.0	1.5	1.7	0.6
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	2.5032 of 5 stars	3.6	1.0	0.0	0.0	3.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	2.50	Moderate Buy	$6.00	105.48% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	627.27% Upside
KRON Kronos Bio	2.33	Hold	$1.63	84.66% Upside
LRMR Larimar Therapeutics	3.10	Buy	$18.43	359.57% Upside

Current Analyst Ratings Breakdown

Latest KRON, BTMD, INMB, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$199.07M	0.73	$0.77 per share	3.81	($1.59) per share	-1.84
INMB INmune Bio	$50K	1,345.20	N/A	N/A	$1.09 per share	2.32
KRON Kronos Bio	$9.85M	5.45	N/A	N/A	$1.45 per share	0.61
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.90	3.24	5.41	N/A	15.73%	-21.00%	18.26%	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
KRON Kronos Bio	-$86.08M	-$1.07	N/A	N/A	N/A	-701.53%	-64.22%	-47.17%	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-58.19%	-50.79%	8/20/2025 (Estimated)

Latest KRON, BTMD, INMB, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
KRON Kronos Bio	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	0.98	1.14
INMB INmune Bio	N/A	4.20	2.64
KRON Kronos Bio	N/A	12.93	12.93
LRMR Larimar Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
INMB INmune Bio	12.72%
KRON Kronos Bio	64.09%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
INMB INmune Bio	35.70%
KRON Kronos Bio	24.40%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	49.44 million	37.57 million	Not Optionable
INMB INmune Bio	10	26.59 million	17.09 million	Optionable
KRON Kronos Bio	100	61.05 million	46.16 million	Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable

KRON, BTMD, INMB, and LRMR Headlines

Recent News About These Companies

Larimar Therapeutics (NASDAQ:LRMR) Issues Earnings Results

1 hour ago | marketbeat.com

Research Analysts Set Expectations for LRMR FY2028 Earnings

August 17 at 11:32 AM | marketbeat.com

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $18.00 by Analysts at JMP Securities

August 17 at 10:18 AM | marketbeat.com

Wedbush Predicts Weaker Earnings for Larimar Therapeutics

August 17 at 3:19 AM | americanbankingnews.com

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

August 16 at 9:32 PM | theglobeandmail.com

Larimar Therapeutics (LRMR) Gets a Buy from Truist Financial

August 16 at 11:29 AM | theglobeandmail.com

Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing

August 16 at 11:29 AM | msn.com

3 Best Stocks to Buy Now, 8/15/2025, According to Top Analysts

August 15 at 8:24 PM | msn.com

Larimar Therapeutics Announces $64.4 Million Stock Offering

August 15 at 8:24 PM | theglobeandmail.com

Larimar Therapeutics price target lowered to $18 from $22 at Citizens JMP

August 15 at 8:24 PM | msn.com

Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses

August 14 at 12:15 AM | tipranks.com

Larimar Beats Q2 Loss Estimates

August 14 at 11:19 AM | aol.comA

Larimar Therapeutics reports Q2 EPS (41c), consensus (49c)

August 14 at 11:19 AM | msn.com

Larimar Therapeutics Reports Q2 2025 Financial Results

August 14 at 11:19 AM | msn.com

Altium Capital Management LLC Reduces Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

August 14 at 7:31 AM | marketbeat.com

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

August 14 at 7:00 AM | globenewswire.com

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest

August 10, 2025 | finance.yahoo.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Director Buys $30,000,000.00 in Stock

August 5, 2025 | marketbeat.com

James E. Flynn Purchases 9,375,000 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock

August 5, 2025 | insidertrades.com

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

July 31, 2025 | globenewswire.com

Larimar Therapeutics shares drop following $60 million public offering

July 30, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRON, BTMD, INMB, and LRMR Company Descriptions

biote NASDAQ:BTMD

$2.92 -0.06 (-2.01%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.92 +0.00 (+0.17%)

As of 08/15/2025 04:47 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

INmune Bio NASDAQ:INMB

$2.53 +0.08 (+3.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.48 -0.05 (-1.94%)

As of 08/15/2025 07:56 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Kronos Bio NASDAQ:KRON

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Larimar Therapeutics NASDAQ:LRMR

$4.01 -0.25 (-5.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.06 +0.05 (+1.35%)

As of 08/15/2025 07:40 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time